NECTIN2 and acute myeloid leukemia: Interestingly, our analysis also demonstrated that AML patients with a CD86low CD112/CD155high phenotype rather displayed a poor prognosis, whereas AML patients with a CD86high CD112/CD155low AML phenotype exhibited a more favorable outcome.